Loading organizations...
§ Private Profile · Palo Alto, CA, USA
Biotechnology company developing protein therapeutics for tissue regeneration, focused on degenerative muscle and metabolic conditions.
Juvena Therapeutics, based in Redwood City, CA, USA, specializes in developing protein therapeutics derived from engineered human stem cells to promote tissue regeneration and treat degenerative diseases. They utilize an AI-enabled JuvNET platform to identify pro-regenerative secreted proteins for various muscle and metabolic conditions, including Myotonic Dystrophy Type 1. Their lead asset, JUV-161, has successfully completed Phase 1 first-in-human safety studies. The venture-backed biotechnology company, with approximately 27 employees, has secured over $105 million in total funding to advance its therapeutic pipeline. Key leaders include Banmeet Anand (SVP Drug Development), Colin Hislop (MD), and Edward Moler (Head of Data Science) guiding its scientific and development initiatives. Founded in 2017 by Hanadie Yousef and Jeremy O’Connell. Its business model centers on venture-backed biotechnology company funded through venture capital, non-dilutive grants, and partnerships.
Juvena Therapeutics has raised $74.5M across 2 funding rounds.
Juvena Therapeutics has raised $74.5M in total across 2 funding rounds.
Juvena Therapeutics has raised $74.5M across 2 funding rounds. Most recently, it raised $33.5M Series B in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 12, 2026 | $33.5M Series B | BEN Hemani | ELI Lilly And Company, Laura Lande Diner, Manta RAY Ventures, Mubadala Capital | Announced |
| Nov 8, 2022 | $41M Series A | Patrick Zhang, Ayman Alabdallah | Jeff Dean, Karl Pfleger, Alumni Ventures, Bison Ventures, BoxOne Ventures, Felicis Ventures, Intersect VC, Irongrey, Manta RAY Ventures, Metamorphic Ventures, Plum Alley, Transform VC | Announced |
Juvena Therapeutics has raised $74.5M in total across 2 funding rounds.
Juvena Therapeutics's investors include Ben Hemani, Eli Lilly and Company, Laura Lande-Diner, Manta Ray Ventures, Mubadala Capital, Patrick Zhang, Ayman AlAbdallah, Jeff Dean, Karl Pfleger, Alumni Ventures, Bison Ventures, BoxOne Ventures.